CCO Management Series
Spanning the Spectrum of Care: Clinical Advances and Practical Applications in Lymphoma
Mechanisms of Action and Clinical Advances in the Treatment of Non-Hodgkin’s Lymphomas |
Module 1 of 2 |
 
- Deborah A. Frieze, PharmD, BCOP
- Alice Mohr, RN, MSN, FNP-BC
|
|
|
Deborah A. Frieze, PharmD, BCOP, and Alice Mohr, RN, MSN, FNP-BC, provide a broad overview of standard and emerging agents and approaches for the treatment of non-Hodgkin’s lymphomas.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the mechanisms of action of different classes of targeted agents for treating patients with non-Hodgkin’s lymphomas
- Discuss different classes of agents being used to treat or investigated for non-Hodgkin’s lymphoma patients
- Summarize the common toxicities associated with the various classes of agents currently in use or under exploration for the treatment of non-Hodgkin’s lymphomas
- Cite recent clinical trial results for the treatment of non-Hodgkin’s lymphomas
Abstract
|
Clinical Considerations and Implications for Optimizing Outcomes in Patients With NHL |
Module 2 of 2 |
- Alice Mohr, RN, MSN, FNP-BC
- Deborah A. Frieze, PharmD, BCOP
|
|
|
Alice Mohr, RN, MSN, FNP-BC, and Deborah A. Frieze, PharmD, BCOP, review dosing regimens, critical safety issues, appropriate preventive care, and supportive care measures associated with the use of various therapeutic modalities for the treatment of non-Hodgkin’s lymphoma.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Apply clinical trial data on the incidence and severity of adverse events associated with chemotherapy agents to optimize management of patient symptoms
- Employ appropriate prophylactic measures and treatment monitoring during targeted agent therapy for non-Hodgkin’s lymphoma patients based on unique toxicities associated with each agent
- Describe appropriate posttreatment safety measures and dosing regimens required when monitoring patients receiving radioimmunotherapy agents
- Identify critical safety and dosing issues associated with the use of therapeutic agents for the treatment of non-Hodgkin’s lymphomas
Abstract
|
Interactive Virtual Presentations
Evolving Options and Challenges in Mantle Cell Lymphoma
|
|
|
Listen to a virtual presentation by Andre Goy, MD, as he provides a comprehensive overview of evolving treatment options for patients with mantle cell lymphoma, and test your knowledge of treatment options in the cases he presents.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss new data on the role of frontline intensive therapeutic strategies for the treatment of mantle cell lymphoma
- Cite recent clinical trial results on the use of new agents for previously untreated and relapsed/refractory mantle cell lymphoma
- Summarize recent data on the value of biomarkers and disease-related factors in predicting patient outcomes
|
Slideset: Evolving Options and Challenges in Mantle Cell Lymphoma
 |
|
Downloadable slideset on the standards of care and emerging novel therapies for the treatment of mantle cell lymphoma
Format: UNKNOWN |
File size: 10.56 MB
| Date posted: 5/21/2009
|
Indolent B-Cell Disorders: Follicular Lymphoma and Waldenström’s Macroglobulinemia
|
|
|
Listen to a virtual presentation by Bruce D. Cheson, MD, as he provides a comprehensive overview of clinical trial data and recommended treatment approaches for follicular lymphoma and Waldenström’s macroglobulinemia patients and tests your knowledge of treatment options in an evolving patient case.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe disease characteristics for diagnosing follicular lymphoma and Waldenström’s macroglobulinemia
- Interpret recent clinical trial data regarding current and novel agents to treat follicular lymphoma and Waldenström’s macroglobulinemia
- Discuss safety profiles associated with current and emerging agents for the treatment of follicular lymphoma and Waldenström’s macroglobulinemia
|
Slideset: Indolent B-Cell Disorders: Follicular Lymphoma and Waldenström’s Macroglobulinemia
 |
|
Downloadable slideset on the standards of care and emerging novel therapies for the treatment of follicular lymphoma and Waldenström’s Macroglobulinemia.
Format: Microsoft PowerPoint (.ppt) |
File size: 9.81 MB
| Date posted: 7/16/2009
|
Therapeutic Approaches in T-Cell Lymphomas: PTCL and CTCL
- Francine Foss, MD, PhD, FACP
|
|
|
Francine Foss, MD, discusses the standard of care and novel agents in development for the treatment of T-cell lymphomas.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Evaluate the efficacy and safety of current treatment options for patients with T-cell lymphomas
- Discuss the role of stem-cell transplantation for the treatment of T-cell lymphomas
- Describe novel treatment options for the treatment of T-cell lymphomas
|
Slideset: Therapeutic Approaches in T-Cell Lymphomas: PTCL and CTCL
 |
|
Downloadable slideset on the standards of care and emerging novel therapies for the treatment of T-Cell lymphomas.
Format: Microsoft PowerPoint (.ppt) |
File size: 3.37 MB
| Date posted: 9/28/2009
|
Clinical Considerations and Strategies for Managing Patients With DLBCL
|
|
|
Richard I. Fisher, MD, discusses clinical considerations and strategies for managing patients with diffuse large B-cell lymphoma.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Compare different schedules of R-CHOP and CHOP for the treatment of diffuse large B-cell lymphoma
- Review historical and new clinical trial results demonstrating the use of treatment regimens for DLBCL
- Describe the role of maintenance therapy for the treatment of diffuse large B-cell lymphoma
- Cite novel agents under investigation for the treatment of diffuse large B-cell lymphoma
|
Slideset: Clinical Considerations and Strategies for Managing Patients With DLBCL
 |
|
Downloadable slideset on the standards of care and emerging novel therapies for the treatment of diffuse large B-cell lymphoma.
Format: Microsoft PowerPoint (.ppt) |
File size: 5.09 MB
| Date posted: 1/15/2010
|
CCO Slideset
Overview of Treatment Options and Clinical Considerations for Managing NHL Patients
 |
|
Review a comprehensive overview of current standards of care for lymphoma, including nursing considerations, such as dosing schedules, adverse effects, and improving patient quality of life.
Format: Microsoft PowerPoint (.ppt) |
File size: 1.79 MB
| Date posted: 4/30/2009
|
Disclaimer:
The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|